

NEW DROPSCREEN™ PRODUCTS LAUNCHED
— ALLOW FASTER ALLERGY TESTING —

Nippon Chemiphar Co., Ltd.
(TSE: 4539)
September 14, 2026

Nippon Chemiphar Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Kazushiro Yamaguchi) has announced that procedures related to national health insurance reimbursement have been completed for the new reagent DropScreen Inhalant Allergens KR-1 (marketing authorization holder: Nippon Chemiphar Co., Ltd.).

The reagent will be launched on September 16, 2026, together with a new measuring device, DropScreen A-2 (marketing authorization holder: Ueda Japan Radio Co., Ltd.).

Launched in February 2020, the DropScreen A-1 and DropScreen specific IgE screening kit ST-1 can measure 41 allergens from a single drop (20 μ L) of blood in 30 minutes, helping to reduce the burden on both patients and healthcare professionals.

They provide a new option for allergy testing, allowing it to be performed in medical institutions where outsourcing to testing laboratories had previously been the practice.

The combination of the new DropScreen A-2 screening kit and new reagent DropScreen Inhalant Allergens KR-1 allows 20 items to be measured—including total IgE—in just 15 minutes. This makes allergy screening even faster.

We will continue contributing to rapid and appropriate allergy screening in clinical settings through the DropScreen series.

For further information contact:

Corporate Planning Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp